Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LMB-100||RG7787|RO-6927005|RO6927005|LMB100||LMB-100 is an immunotoxin that targets mesothelin, potentially resulting in antitumor activity (PMID: 27863199, PMID: 32611684).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02810418||Phase Ib/II||LMB-100 LMB-100 + Nab-paclitaxel||Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors||Active, not recruiting|
|NCT02798536||Phase I||LMB-100 LMB-100 + Nab-paclitaxel||Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma||Active, not recruiting|